Yi Wang

Practice Areas

Position: Partner, Head of Capital Markets Group

Office: Shanghai

Professional Experience & Core Expertise: Mr. Wang has been practicing for more than 20 years with leading PRC firms and international firms in Beijing, Hong Kong, and Shanghai. He specializes in a wide range of domestic and overseas listings, bond and stock issuances, M&A of listed companies, and private equity fund formation and investments.

Career

Professional Qualifications: PRC Bar Qualification；LL.M. from University of California, Berkeley

Institutional Roles (more details): Mr. Wang currently serves as a director for several listed companies, insurance companies, private equity funds, and other financial institutions. Previously served as an Independent Director of Jinhong Fashion Group Co., Ltd. (May 31, 2016 - June 5, 2019).

Personal

Mr. Wang Yi currently serves on several key internal committees at JunHe LLP, holding leadership roles that reflect his commitment to the firm's governance and development:

Member of the Strategic Development Committee: Participates in the firm's strategic planning and development discussions, analyzing market trends and industry changes to provide strategic recommendations that ensure JunHe's sustainable growth and competitive advantage.

Chair/Convener of the Review Committee: Oversees the recruitment process for external partners and the performance evaluation of internal partners, ensuring all partners meet JunHe's standards and expectations.

Member of the Professional Development Committee: Provides training, guidance, and support to associates, ensuring clear and reasonable career development paths and facilitating both personal and professional growth.

Member of the Internal Review Committee: Serves as a risk management and compliance guardian for JunHe's securities practice, identifying and assessing potential risks, and ensuring compliance with laws, regulations, and industry standards to safeguard the firm's reputation and professionalism.

Clients

PE/VC Funds: Sequoia Capital, China Everbright, PAG, CCB International, CITIC Capital, Hillhouse Capital, Advent International, Warburg Pincus, CDH Investments, FountainVest Partners, etc.

Work Highlights

2019 – Harbin Pharmaceutical's US$300 Million Investment in GNC

As the lead partner and exclusive PRC legal advisor to Harbin Pharmaceutical Co., Ltd. (600664), Mr. Wang advised on its US$299.95 million subscription of convertible preferred shares of NYSE-listed GNC Holdings, Inc. (NYSE:GNC). Upon conversion, Harbin Pharmaceutical became GNC's single largest shareholder with a 40.1% equity interest. This cross-border strategic investment, completed against the backdrop of the China-US trade war, involved two dual-listed companies and lasted over one year.

2020 – First WVR IPO on A-Share Market – UCloud

Mr. Wang served as the lead partner for the issuer, assisting UCloud Technology Co., Ltd. in its successful listing on the STAR Market of the Shanghai Stock Exchange, setting a precedent as the first weighted voting rights (WVR) IPO on the A-share market.

2023 – Canadian Solar (CSI Solar) – STAR Market Spin-off IPO

Mr. Wang acted as the lead partner and issuer's counsel for CSI Solar's A-share IPO on the STAR Market (Stock Code: 688472). CSI Solar was spun off from its NASDAQ-listed parent, Canadian Solar Inc. (CSIQ), representing the largest spin-off IPO financing project since the full implementation of the registration-based IPO system in 2023, with total proceeds of approximately RMB 6 billion.

2025 – WeRide Inc. – Dual Primary Listing on HKEX

As the lead partner of JunHe's New York office, Mr. Wang acted as the Company's U.S. counsel for WeRide's HKEX listing (Stock Code: 0800.HK). WeRide became the world's first autonomous driving company to achieve dual-primary listings on both NASDAQ (2024) and HKEX (2025).

2025 – Fibocom Wireless Inc. – A+H Dual Listing on HKEX

Mr. Wang served as the lead partner and PRC legal advisor to the sole sponsor and underwriters for Fibocom's H-share listing on HKEX (Stock Code: 0638.HK). Fibocom, already listed on Shenzhen ChiNext Board (Stock Code: 300638), successfully achieved A+H dual listing with total proceeds of approximately HK$2.9 billion.

2026 – Qiming Venture Partners – Acquisition of A-Share Listed Tianmai Technology

Mr. Wang served as the lead partner and exclusive legal advisor to Qiming Venture Partners' M&A fund in its acquisition of control of Shenzhen-listed Tianmai Technology (Stock Code: 300807). This was the first market-announced private equity fund acquisition of a listed company following the CSRC's "M&A Six Measures" (2024).

Industry Sector Expertise

Mr. Wang has deep expertise across three core sectors. In Capital Markets, he has extensive experience in domestic and overseas IPOs, refinancings, and bond issuances, particularly in complex projects involving cross-border structures (red-chip/VIE) and innovative governance structures (WVR). He has successfully advised on more than 50 IPOs across the A-share, Hong Kong, and U.S. markets. In TMT (Technology, Media and Telecoms), he has been consecutively recommended by Legal 500 and other authoritative bodies for many years. He possesses a profound understanding of the regulatory dynamics and capital market pathways for sectors including the internet, cloud computing, online services, and AI, having advised leading companies such as UCloud, WeRide, Xiaomi, and Liepin. In Private Equity & M&A, he is proficient in the full lifecycle of private equity funds, from fundraising and formation to investments and exits, regularly representing top-tier funds such as Sequoia Capital, Warburg Pincus, CDH Investments, and Qiming Venture Partners in strategic investments and M&A transactions involving A-share listed companies.

Expert in these Jurisdictions

• Mainland China: Proficient in A-share (STAR Market and Main Board) listing rules, listed company M&A and restructuring, and private equity fund regulations. He has advised on numerous landmark A-share transactions, including the first WVR IPO on the STAR Market (UCloud).

• Hong Kong SAR: Very familiar with the HKEX listing rules and has extensive experience in H-share and red-chip structured projects, having advised on dual-primary listings (WeRide), A+H dual listings (Fibocom), and the first Hong Kong WVR IPO (Xiaomi).

• United States: Substantial experience assisting Chinese companies with listings on NASDAQ and the NYSE, including WeRide's NASDAQ listing (2024) and Atour's NASDAQ listing, as well as cross-border investments involving NYSE-listed companies such as Harbin Pharmaceutical's investment in GNC.

Languages Spoken

Chinese, English

Experience

Mr. Wang joined JunHe LLP in 2004 and has been practicing for more than 20 years. He is currently a Partner in the Capital Markets Department and the Head of the Capital Markets Group. Prior to joining JunHe, he worked with leading PRC and international law firms in Beijing, Hong Kong, and Shanghai, which provided him with valuable cross-border and cross-jurisdictional experience. He was promoted to Partner at JunHe in 2010. His career milestones include leading the first WVR IPO on the A-share market (UCloud) in 2020, serving as the lead partner for the largest spin-off IPO since the full implementation of the registration-based IPO system (CSI Solar) in 2023, and advising on the world's first dual-primary listing of an autonomous driving company (WeRide) in 2025. In 2022, he was recognized by ALB as one of the "Asia Super 50 T Lawyers." Throughout his career, he has consistently been ranked as a leading lawyer in Capital Markets by Chambers and Partners (2013-2025) and in TMT by The Legal 500.

Education

Awards